188 Chapter 14 · Philadelphia Chromosome-Positive <strong>Acute</strong> Lymphoblastic Leukemia 81. Leis JF, Stepan DE, Curtin PT, Ford JM, Peng B, Schubach S, et al. (2004) Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma 45(4):695–698 82. Lee KH, Lee JH, Choi SJ, Seol M, Lee YS, Kim WK, et al. (2005) Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 19(9):1509–1516 83. Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, et al. (2004) Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 104(12):3507–3512 84. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW, et al. (2005) The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 105(9):3449–3457 85. Lee S, Kim DW, Kim YJ, Chung NG, Kim YL, Hwang JY, et al. (2003) Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 102(8):3068–3070 86. Wassmann B, Pfeifer H, Stadler M, Bornhauser M, Bug G, Scheuring UJ, et al. (2005) Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphiapositive acute lymphoblastic leukemia (Ph+ ALL). Blood 106(2): 458–463 87. von Bubnoff N, Peschel C, Duyster J (2003) Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): A targeted oncoprotein strikes back. Leukemia 17(5):829–838 88. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531): 876– 880 89. Hato T, Yamanouchi J, Tamura T, Hojo N, Niiya Y, Kohno M, et al. (2004) Existence of leukemic clones resistant to both imatinib mesylate and rituximab before drug therapies in a patient with Philadelphia chromosome-positive acute lymphocytic leukemia. Int J Hematol 80(1):62–66 90. Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D, et al. (2003) Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102(2):659–661 91. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2):129–141 92. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682):399–401 93. Harata M, Soda Y, Tani K, Ooi J, Takizawa T, Chen M, et al. (2004) CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood 104(5):1442–1449 94. Barrett AJ HM, Ash RC, Atkinson K, Gale RP, Goldman JM, Henslee- Downey PJ, Herzig RH, Speck B, Zwaan FE, et al. (1992) Bone mar- row transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 79(30):67–70 95. Dunlop LC PR, Singhal S, Treleaven JG, Swansbury GJ, Meller S, Pinkerton CR, Horton C, Mehta J (1996) Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 17(36):5–9 96. Kroger N, Kruger W, Wacker-Backhaus G, Hegewisch-Becker S, Stockschlader M, Fuchs N, et al. (1998) Intensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 22(11):1029–1033 97. Esperou H, Boiron JM, Cayuela JM, Blanchet O, Kuentz M, Jouet JP, et al. (2003) A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 31(10):909–918 98. Lee S, Kim DW, Cho B, Kim YJ, Kim YL, Hwang JY, et al. (2003) Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: The potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 120(1):145–153 99. Matsue K, Tabayashi T, Yamada K, Takeuchi M (2002) Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 29(1):63–66 100. Sierra J, Radich J, Hansen JA, Martin PJ, Petersdorf EW, Bjerke J, et al. (1997) Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 90(4):1410–1414 101. Snyder DS, Nademanee AP, O‘Donnell MR, Parker PM, Stein AS, Margolin K, et al. (1999) Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 13(12):2053–2058 102. Chao NJ, Blume KG, Forman SJ, Snyder DS (1995) Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 85(11):3353–3354 103. Preudhomme C, Henic N, Cazin B, Lai JL, Bertheas MF, Vanrumbeke M, et al. (1997) Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL). Leukemia 11(2):294–298 104. Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C, et al. (2005) Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 19(4):628–635 105. Mitterbauer G, Nemeth P, Wacha S, Cross NC, Schwarzinger I, Jaeger U, et al. (1999) Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction. Br J Haematol 106(3):634–643 106. Scheuring UJ, Pfeifer H, Wassmann B, Bruck P, Atta J, Petershofen EK, et al. (2003) Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive
a References 189 acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Blood 101(1):85–90 107. Scheuring UJ, Pfeifer H, Wassmann B, Bruck P, Gehrke B, Petershofen EK, et al. (2003) Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia 17(9):1700–1706 108. Miyamura K, Tanimoto M, Morishima Y, Horibe K, Yamamoto K, Akatsuka M, et al. (1992) Detection of Philadelphia chromosomepositive acute lymphoblastic leukemia by polymerase chain re- action: Possible eradication of minimal residual disease by marrow transplantation. Blood 79(5):1366–1370 109. Kohler S, Galili N, Sklar JL, Donlon TA, Blume KG, Cleary ML (1990) Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia. Leukemia 4(8):541–547 110. Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ, et al. (1998) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 92(11):4072–4079
- Page 1 and 2:
E.H. Estey · S.H. Faderl · H. M.
- Page 3 and 4:
E. H. Estey Department of Leukemia
- Page 5 and 6:
VI Table of Contents 14 Philadelphi
- Page 7 and 8:
VIII Contributors S. H. Faderl Depa
- Page 9 and 10:
X Contributors D. Wartenberg Depart
- Page 11 and 12:
Therapy of AML Elihu Estey Contents
- Page 13 and 14:
a 1.2 · Standard Therapy 3 Table 1
- Page 15 and 16:
a 1.2 · Standard Therapy 5 Table 1
- Page 17 and 18:
a 1.2 · Standard Therapy 7 tween G
- Page 19 and 20:
a 1.2 · Standard Therapy 9 Fig. 1.
- Page 21 and 22:
a 1.2 · Standard Therapy 11 of tre
- Page 23 and 24:
a 1.2 · Standard Therapy 13 Table
- Page 25 and 26:
a 1.2 · Standard Therapy 15 permit
- Page 27 and 28:
a References 17 19. Care RS, Valk P
- Page 29 and 30:
a References 19 6-thioguanine in th
- Page 31 and 32:
Acute Myeloid Leukemia: Epidemiolog
- Page 33 and 34:
a 3.1 · Epidemiology 49 3.1.4 Gend
- Page 35 and 36:
a 3.2 · Etiology 51 part of the in
- Page 37 and 38:
a 3.2 · Etiology 53 for the develo
- Page 39 and 40:
a References 55 38. Crane MM, Stom
- Page 41 and 42:
Relapsed and Refractory Acute Myelo
- Page 43 and 44:
a 4.2 · Prognostic Factors in Pati
- Page 45 and 46:
a 4.3 · Treatment of Relapsed and
- Page 47 and 48:
a 4.4 · Hematopoietic Stem Cell Tr
- Page 49 and 50:
a 4.6 · Gemtuzumab Ozogamicin 65 T
- Page 51 and 52:
a 4.7 · Relapsed and Refractory Ac
- Page 53 and 54:
a 4.7 · Relapsed and Refractory Ac
- Page 55 and 56:
a References 71 The ability of immu
- Page 57 and 58:
a References 73 39. Vogler WR, McCa
- Page 59 and 60:
a References 75 95. Sievers EL, Lar
- Page 61 and 62:
Part II - Acute Lymphoblastic Leuke
- Page 63 and 64:
78 Chapter 5 · Acute Lymphoblastic
- Page 65 and 66:
80 Chapter 5 · Acute Lymphoblastic
- Page 67 and 68:
82 Chapter 5 · Acute Lymphoblastic
- Page 69 and 70:
84 Chapter 5 · Acute Lymphoblastic
- Page 71 and 72:
86 Chapter 5 · Acute Lymphoblastic
- Page 73 and 74:
88 Chapter 5 · Acute Lymphoblastic
- Page 75 and 76:
90 Chapter 5 · Acute Lymphoblastic
- Page 77 and 78:
92 Chapter 5 · Acute Lymphoblastic
- Page 79 and 80:
Molecular Biology and Genetics Meir
- Page 81 and 82:
a 6.3 · Structural Aberrations 97
- Page 83 and 84:
a 6.3 · Structural Aberrations 99
- Page 85 and 86:
a 6.5 · Molecular Aberrations 101
- Page 87 and 88:
a References 103 clear that homozyg
- Page 89 and 90:
a References 105 53. Chim CS, Tam C
- Page 91 and 92:
a References 107 122. Lennard L, Li
- Page 93 and 94:
Diagnosis of Acute Lymphoblastic Le
- Page 95 and 96:
a 8.3 · Cytochemistry and Immunoph
- Page 97 and 98:
a 8.5 · Cytogenetic and Molecular
- Page 99 and 100:
a 8.5 · Cytogenetic and Molecular
- Page 101 and 102:
a References 127 including the reti
- Page 103 and 104:
a References 129 47. Kita K, Shirak
- Page 105 and 106:
Acute Lymphoblastic Leukemia: Clini
- Page 107 and 108:
a 7.3 · Diagnosis 111 or neoplasti
- Page 109 and 110:
a 7.3 · Diagnosis 113 Fig. 7.2. Hi
- Page 111 and 112:
a 7.3 · Diagnosis 115 The vast maj
- Page 113 and 114:
a References 117 dren: Biologic bas
- Page 115 and 116:
General Approach to the Therapy of
- Page 117 and 118:
a 9.3 · New Agents 133 dose methot
- Page 119 and 120: a References 135 4. Gökbuget N, Ho
- Page 121 and 122: 138 Chapter 10 · Recent Clinical T
- Page 123 and 124: 140 Chapter 10 · Recent Clinical T
- Page 125 and 126: 142 Chapter 10 · Recent Clinical T
- Page 127 and 128: 144 Chapter 10 · Recent Clinical T
- Page 129 and 130: 146 Chapter 11 · Conventional Ther
- Page 131 and 132: 148 Chapter 11 · Conventional Ther
- Page 133 and 134: 150 Chapter 11 · Conventional Ther
- Page 135 and 136: 152 Chapter 11 · Conventional Ther
- Page 137 and 138: 154 Chapter 11 · Conventional Ther
- Page 139 and 140: 156 Chapter 11 · Conventional Ther
- Page 141 and 142: 158 Chapter 11 · Conventional Ther
- Page 143 and 144: ALL Therapy: Review of the MD Ander
- Page 145 and 146: a 12.2 · The Hyper-CVAD Regimen in
- Page 147 and 148: a 12.3 · Subset-Specific Approache
- Page 149 and 150: Treatment of Adult ALL According to
- Page 151 and 152: a 13.2 · Therapy for Younger (15-6
- Page 153 and 154: a 13.3 · Therapy of Ph/BCR-ABL-Pos
- Page 155 and 156: a 13.5 · Prognostic Factors 173 13
- Page 157 and 158: a References 175 Only patients with
- Page 159 and 160: Philadelphia Chromosome-Positive Ac
- Page 161 and 162: a 14.2 · Molecular Biology of the
- Page 163 and 164: a 14.3 · Treatment of Ph+ ALL 181
- Page 165 and 166: a 14.4 · Hematopoietic Stem Cell T
- Page 167 and 168: a References 185 2. Kurzrock R, Sht
- Page 169: a References 187 56. Mori T, Manabe
- Page 173 and 174: 192 Chapter 15 · Burkitt’s Acute
- Page 175 and 176: 194 Chapter 15 · Burkitt’s Acute
- Page 177 and 178: 196 Chapter 15 · Burkitt’s Acute
- Page 179 and 180: 198 Chapter 15 · Burkitt’s Acute
- Page 181 and 182: 200 Chapter 15 · Burkitt’s Acute
- Page 183 and 184: 202 Chapter 15 · Burkitt’s Acute
- Page 185 and 186: 204 Chapter 16 · Treatment of Lymp
- Page 187 and 188: 206 Chapter 16 · Treatment of Lymp
- Page 189 and 190: 208 Chapter 16 · Treatment of Lymp
- Page 191 and 192: 210 Chapter 16 · Treatment of Lymp
- Page 193 and 194: 212 Chapter 16 · Treatment of Lymp
- Page 195 and 196: 214 Chapter 16 · Treatment of Lymp
- Page 197 and 198: 216 Chapter 17 · The Role of Allog
- Page 199 and 200: 218 Chapter 17 · The Role of Allog
- Page 201 and 202: 220 Chapter 17 · The Role of Allog
- Page 203 and 204: 222 Chapter 17 · The Role of Allog
- Page 205 and 206: 224 Chapter 17 · The Role of Allog
- Page 207 and 208: 226 Chapter 17 · The Role of Allog
- Page 209 and 210: 228 Chapter 17 · The Role of Allog
- Page 211 and 212: 230 Chapter 18 · The Role of Autol
- Page 213 and 214: 232 Chapter 18 · The Role of Autol
- Page 215 and 216: 234 Chapter 18 · The Role of Autol
- Page 217 and 218: 236 Chapter 18 · The Role of Autol
- Page 219 and 220: 238 Chapter 19 · Novel Therapies i
- Page 221 and 222:
240 Chapter 19 · Novel Therapies i
- Page 223 and 224:
242 Chapter 19 · Novel Therapies i
- Page 225 and 226:
244 Chapter 19 · Novel Therapies i
- Page 227 and 228:
246 Chapter 19 · Novel Therapies i
- Page 229 and 230:
248 Chapter 20 · Minimal Residual
- Page 231 and 232:
250 Chapter 20 · Minimal Residual
- Page 233 and 234:
252 Chapter 20 · Minimal Residual
- Page 235 and 236:
254 Chapter 20 · Minimal Residual
- Page 237 and 238:
256 Chapter 20 · Minimal Residual
- Page 239 and 240:
258 Chapter 20 · Minimal Residual
- Page 241 and 242:
260 Chapter 20 · Minimal Residual
- Page 243 and 244:
262 Chapter 20 · Minimal Residual
- Page 245 and 246:
264 Chapter 21 · Central Nervous S
- Page 247 and 248:
266 Chapter 21 · Central Nervous S
- Page 249 and 250:
268 Chapter 21 · Central Nervous S
- Page 251 and 252:
270 Chapter 21 · Central Nervous S
- Page 253 and 254:
272 Chapter 21 · Central Nervous S
- Page 255 and 256:
274 Chapter 21 · Central Nervous S
- Page 257 and 258:
276 Chapter 22 · Relapsed Acute Ly
- Page 259 and 260:
278 Chapter 22 · Relapsed Acute Ly
- Page 261 and 262:
Emergencies in Acute Lymphoblastic
- Page 263 and 264:
a 23.5 · Hyperleukocytosis 283 LA
- Page 265 and 266:
a 23.9 · Neurological Complication
- Page 267 and 268:
a References 287 29. Hingorani AD,
- Page 269 and 270:
Subject Index A aberrant methylatio
- Page 271 and 272:
a Subject Index 291 CREB, see enhan
- Page 273 and 274:
a Subject Index 293 MUD, see matche